EMS not allowed to participate in Hypera-Boehringer deal review in Brazil
MLex Summary: Brazilian pharmaceutical giant EMS can't participate in the national competition watchdog's review of Hypera's planned buyout of Boehringer Ingelheim's antispasmodics and analgesics brands. The Administrative Council for Economic Defense said...To view the full article, register now.
Already a subscriber? Click here to view full article